Literature DB >> 21852546

Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Clayton Harro1, Subhra Chakraborty, Andrea Feller, Barbara DeNearing, Alicia Cage, Malathi Ram, Anna Lundgren, Ann-Mari Svennerholm, August L Bourgeois, Richard I Walker, David A Sack.   

Abstract

Enterotoxigenic Escherichia coli (ETEC) strain H10407 (serotype O78:H11 producing heat-labile toxin [LT], heat-stable toxin [ST], and colonization factor I [CFA/I]) induces reliably high diarrheal attack rates (ARs) in a human challenge model at doses of ≥10(9) CFU. A descending-dose challenge study was conducted with changes to the standard fasting time and buffer formulation, seeking conditions that permit lower inocula while maintaining reproducibly high ARs. In cohort 1, 20 subjects were fasted overnight and randomized 1:1:1:1 to receive H10407 at doses of 10(8) CFU with bicarbonate, 10(8) CFU with CeraVacx, 10(7) CFU with bicarbonate, or 10(7) CFU with CeraVacx. Subsequent cohorts received H10407 (10(7) CFU with bicarbonate) with similar fasting conditions. Cohort 2 included 15 ETEC-naïve volunteers. Cohort 3 included 10 ETEC-naïve volunteers and 10 rechallenged volunteers. In all, 25/35 (71%) ETEC-naïve recipients of 10(7) CFU of H10407 developed moderate or severe diarrhea (average maximum stool output/24 h = 1,042 g), and most (97%) shed H10407 (maximum geometric mean titer = 7.5 × 10(7) CFU/gram of stool). Only one of 10 rechallenged volunteers developed diarrhea. These rechallenged subjects had reduced intestinal colonization, reflected by quantitative microbiology of fecal samples. Among the 35 ETEC-naïve subjects, anti-lipopolysaccharide (LPS) O78 serum antibody responses were striking, with positive IgA and IgG antibody responses in 33/35 (94%) and 25/35 (71%), respectively. Anti-heat-labile enterotoxin (LTB) serum IgA and IgG responses developed in 19/35 (54%) and 14/35 (40%) subjects, respectively. Anti-CFA/I serum IgA and IgG responses were detected in 15/35 (43%) and 8/35 (23%) subjects. After the second challenge, participants exhibited blunted anti-LPS and -LTB responses but a booster response to CFA/I. This ETEC model should prove useful in the future evaluation of ETEC vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21852546      PMCID: PMC3187035          DOI: 10.1128/CVI.05194-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  35 in total

1.  Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2006-03-17

2.  Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease.

Authors:  R B Sack; S L Gorbach; J G Banwell; B Jacobs; B D Chatterjee; R C Mitra
Journal:  J Infect Dis       Date:  1971-04       Impact factor: 5.226

Review 3.  Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention.

Authors:  Firdausi Qadri; Ann-Mari Svennerholm; A S G Faruque; R Bradley Sack
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

4.  Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.

Authors:  Mitchell B Cohen; Ralph A Giannella; Judy Bean; David N Taylor; Susan Parker; Amy Hoeper; Stephen Wowk; Jennifer Hawkins; Sims K Kochi; Gilbert Schiff; Kevin P Killeen
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

5.  Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.

Authors:  T S Coster; M K Wolf; E R Hall; F J Cassels; D N Taylor; C T Liu; F C Trespalacios; A DeLorimier; D R Angleberger; C E McQueen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

Review 6.  Vaccines against enterotoxigenic Escherichia coli.

Authors:  Ann-Mari Svennerholm; Joshua Tobias
Journal:  Expert Rev Vaccines       Date:  2008-08       Impact factor: 5.217

7.  Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

Authors:  Robin McKenzie; Malabi M Venkatesan; Marcia K Wolf; Dilara Islam; Shannon Grahek; Andrea M Jones; Arlene Bloom; David N Taylor; Thomas L Hale; A Louis Bourgeois
Journal:  Vaccine       Date:  2008-04-16       Impact factor: 3.641

Review 8.  Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease.

Authors:  Richard I Walker; Duncan Steele; Teresa Aguado
Journal:  Vaccine       Date:  2006-12-19       Impact factor: 3.641

9.  Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

Authors:  Robin McKenzie; A Louis Bourgeois; Sarah A Frech; David C Flyer; Arlene Bloom; Kazem Kazempour; Gregory M Glenn
Journal:  Vaccine       Date:  2007-01-23       Impact factor: 3.641

10.  Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico.

Authors:  David A Sack; Janet Shimko; Olga Torres; August L Bourgeois; Domingo Sanchez Francia; Björn Gustafsson; Anders Kärnell; Iréne Nyquist; Ann-Mari Svennerholm
Journal:  Vaccine       Date:  2007-04-04       Impact factor: 3.641

View more
  40 in total

1.  A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.

Authors:  Clayton Harro; David Sack; A Louis Bourgeois; R Walker; Barbara DeNearing; Andrea Feller; Subhra Chakraborty; Charlotte Buchwaldt; Michael J Darsley
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

2.  An emm-type specific qPCR to track bacterial load during experimental human Streptococcus pyogenes pharyngitis.

Authors:  Loraine V Fabri; Kristy I Azzopardi; Joshua Osowicki; Hannah R Frost; Pierre R Smeesters; Andrew C Steer
Journal:  BMC Infect Dis       Date:  2021-05-21       Impact factor: 3.090

3.  Development and accuracy of quantitative real-time polymerase chain reaction assays for detection and quantification of enterotoxigenic Escherichia coli (ETEC) heat labile and heat stable toxin genes in travelers' diarrhea samples.

Authors:  Bonnie P Youmans; Nadim J Ajami; Zhi-Dong Jiang; Joseph F Petrosino; Herbert L DuPont; Sarah K Highlander
Journal:  Am J Trop Med Hyg       Date:  2013-11-04       Impact factor: 2.345

4.  Providing Structure to Enterotoxigenic Escherichia coli Vaccine Development.

Authors:  James M Fleckenstein
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

5.  Enterotoxigenic Escherichia coli prevents host NF-κB activation by targeting IκBα polyubiquitination.

Authors:  Xiaogang Wang; Philip R Hardwidge
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

6.  Establishment and Validation of Pathogenic CS17+ and CS19+ Enterotoxigenic Escherichia coli Challenge Models in the New World Primate Aotus nancymaae.

Authors:  Eric R Hall; Aisling O'Dowd; Julianne E Rollenhagen; Nereyda Espinoza; Gladys Nunez; Stephen J Savarino
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

7.  Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans.

Authors:  William E Yang; Sunil Suchindran; Bradly P Nicholson; Micah T McClain; Thomas Burke; Geoffrey S Ginsburg; Clayton D Harro; Subhra Chakraborty; David A Sack; Christopher W Woods; Ephraim L Tsalik
Journal:  J Infect Dis       Date:  2016-01-18       Impact factor: 5.226

8.  Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.

Authors:  Subhra Chakraborty; Arlo Randall; Tim J Vickers; Doug Molina; Clayton D Harro; Barbara DeNearing; Jessica Brubaker; David A Sack; A Louis Bourgeois; Philip L Felgner; Xiaowu Liang; Sachin Mani; Heather Wenzel; R Reid Townsend; Petra E Gilmore; Michael J Darsley; David A Rasko; James M Fleckenstein
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

9.  The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Authors:  Michael J Darsley; Subhra Chakraborty; Barbara DeNearing; David A Sack; Andrea Feller; Charlotte Buchwaldt; A Louis Bourgeois; Richard Walker; Clayton D Harro
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

10.  Highlights of the 8th International Conference on Vaccines for Enteric Diseases: the Scottish Encounter To Defeat Diarrheal Diseases.

Authors:  Sharon M Tennant; A Duncan Steele; Marcela F Pasetti
Journal:  Clin Vaccine Immunol       Date:  2016-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.